Both Adial Pharmaceuticals Inc. (NASDAQ:ADIL) and Galapagos NV (NASDAQ:GLPG) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adial Pharmaceuticals Inc. | 2 | 0.00 | 6.53M | -2.27 | 0.00 |
| Galapagos NV | 164 | 0.00 | 37.11M | -1.69 | 0.00 |
Table 1 highlights Adial Pharmaceuticals Inc. and Galapagos NV’s top-line revenue, earnings per share and valuation.
Profitability
Table 2 provides us the return on equity, return on assets and net margins of both companies.
| Net Margins | Return on Equity | Return on Assets | |
| Adial Pharmaceuticals Inc. | 410,769,327.55% | -281.4% | -251.1% |
| Galapagos NV | 22,601,863.69% | 0% | 0% |
Analyst Ratings
The Recommendations and Ratings for Adial Pharmaceuticals Inc. and Galapagos NV are featured in the next table.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Adial Pharmaceuticals Inc. | 0 | 0 | 0 | 0.00 |
| Galapagos NV | 0 | 0 | 3 | 3.00 |
Meanwhile, Galapagos NV’s consensus target price is $199, while its potential upside is 29.34%.
Institutional and Insider Ownership
Institutional investors owned 16.8% of Adial Pharmaceuticals Inc. shares and 16.78% of Galapagos NV shares. Insiders owned roughly 3.4% of Adial Pharmaceuticals Inc.’s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Adial Pharmaceuticals Inc. | -9.55% | 6.51% | -33.82% | -67.15% | -55.07% | -64.84% |
| Galapagos NV | -2.84% | 32.93% | 52.92% | 71.36% | 55.03% | 89.01% |
For the past year Adial Pharmaceuticals Inc. had bearish trend while Galapagos NV had bullish trend.
Summary
On 7 of the 10 factors Galapagos NV beats Adial Pharmaceuticals Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
